JP Morgan Chase’s NxStage Medical Inc. NXTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-1,225,737
| Closed | -$35.1M | – | 6230 |
|
|
2018
Q4 | $35.1M | Buy |
1,225,737
+38,487
| +3% | +$1.09M | 0.01% | 1089 |
|
|
2018
Q3 | $33.1M | Buy |
1,187,250
+427,745
| +56% | +$12M | 0.01% | 1279 |
|
|
2018
Q2 | $21.2M | Sell |
759,505
-684,166
| -47% | -$18.3M | ﹤0.01% | 1534 |
|
|
2018
Q1 | $35.9M | Sell |
1,443,671
-370,977
| -20% | -$9.02M | 0.01% | 1130 |
|
|
2017
Q4 | $44M | Sell |
1,814,648
-56,093
| -3% | -$1.48M | 0.01% | 1054 |
|
|
2017
Q3 | $51.5M | Buy |
1,870,741
+1,869,961
| +239,739% | +$49.9M | 0.01% | 914 |
|
|
2017
Q2 | $20K | Buy |
780
+110
| +16% | +$2.72K | ﹤0.01% | 4546 |
|
|
2017
Q1 | $18K | Buy |
670
+77
| +13% | +$2.13K | ﹤0.01% | 4726 |
|
|
2016
Q4 | $16K | Buy |
+593
| New | +$14.7K | ﹤0.01% | 4741 |
|
|
2016
Q1 | – | Sell |
-238
| Closed | -$5K | – | 5089 |
|
|
2015
Q4 | $5K | Buy |
+238
| New | +$4.43K | ﹤0.01% | 4362 |
|
|
2015
Q3 | – | Sell |
-23,467
| Closed | -$335K | – | 4183 |
|
|
2015
Q2 | $335K | Buy |
23,467
+6,023
| +35% | +$102K | ﹤0.01% | 3686 |
|
|
2015
Q1 | $302K | Buy |
+17,444
| New | +$308K | ﹤0.01% | 3708 |
|
|
2014
Q1 | – | Sell |
-42,636
| Closed | -$426K | – | 4064 |
|
|
2013
Q4 | $426K | Buy |
42,636
+25,000
| +142% | +$284K | ﹤0.01% | 3553 |
|
|
2013
Q3 | $232K | Sell |
17,636
-2,854
| -14% | -$37.4K | ﹤0.01% | 3988 |
|
|
2013
Q2 | $293K | Buy |
+20,490
| New | +$258K | ﹤0.01% | 3828 |
|
Other funds holding NXTM
JP Morgan Chase's NXTM Position: Q1 2019 in Review
JP Morgan Chase sold out of NxStage Medical Inc. (NXTM) in Q1 2019, closing a stake of 1,225,737 shares — an estimated $35.1M sold.
JP Morgan Chase first reported a position in NXTM in Q2 2013 and held it in 15 quarters. The position peaked at $51.5M in Q3 2017. 1 fund tracked by Wall St. Rank holds NXTM as of Q1 2019.
- JP Morgan Chase reported no remaining NxStage Medical Inc. position as of Q1 2019 after selling out during the quarter.
- JP Morgan Chase sold 1,225,737 NxStage Medical Inc. shares in Q1 2019, an estimated $35.1M.
- JP Morgan Chase first reported a position in NxStage Medical Inc. in Q2 2013 and held it in 15 quarters.
- JP Morgan Chase's NxStage Medical Inc. position peaked at $51.5M in Q3 2017.
- 1 fund tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2019.
Based on JP Morgan Chase's 13F filing for Q1 2019, filed 7 May 2019.